Soluble Heparin-binding EGF-like Growth Factor (HB-EGF) Detected by Newly Developed Immuno-PCR Method is a Clear-cut Serological Biomarker for Ovarian Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2012 Nov 13

PMID 23145209

Citations 5

Authors

Noriyuki Kasai

Kazuhiro Kobayashi

Shinobu Shioya

Yukitaka Yoshikawa

Fusanori Yotsumoto

Shingo Miyamoto

Eisuke Mekada

Junichi Enokizono

Affiliations

Soon will be listed here.

Abstract

Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family of growth factors that bind to and activate the EGF receptor. HB-EGF is synthesized as a membrane-anchored protein (proHB-EGF), and then proteolytically cleaved, resulting in the mitogenically active soluble form. HB-EGF plays pivotal roles in pathophysiological processes such as development and cell proliferation. In this study, we developed an immuno-PCR system for the determination of soluble HB-EGF concentrations in human serum. Utilizing a monoclonal antibody with neutralizing activity against HB-EGF as a capture antibody resulted in increasing selectivity for an active form of HB-EGF in serum, and immuno-PCR system improved its sensitivity compared to the currently available methods. As a result of measurement of HB-EGF in 20 ovarian cancer patients and 20 healthy volunteers, ovarian cancer patients showed significantly higher concentrations than healthy volunteers (P< 0.05), which indicates that soluble HB-EGF detected by newly developed immuno-PCR system can be useful serological biomarkers such as a diagnostic biomarker for ovarian cancer, and a predictive and pharmacodynamic biomarker for anti-HB-EGF targeted therapies under development.

Citing Articles

Nectin-4 as Blood-Based Biomarker Enables Detection of Early Ovarian Cancer Stages.

Rogmans C, Feuerborn J, Treeck L, Tribian N, Florkemeier I, Arnold N Cancers (Basel). 2022; 14(23).

PMID: 36497350 PMC: 9739558. DOI: 10.3390/cancers14235867.

Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines.

Shen Y, Ruan L, Lian C, Li R, Tu Z, Liu H Cell Death Discov. 2019; 5:82.

PMID: 30937184 PMC: 6433920. DOI: 10.1038/s41420-019-0163-9.

Proximity assays for sensitive quantification of proteins.

Greenwood C, Ruff D, Kirvell S, Johnson G, Dhillon H, Bustin S Biomol Detect Quantif. 2016; 4:10-6.

PMID: 27077033 PMC: 4822221. DOI: 10.1016/j.bdq.2015.04.002.

Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.

Sarantopoulos J, Mita M, Birrer M, Cranmer L, Campos L, Zhang X Target Oncol. 2015; 11(3):317-27.

PMID: 26507836 DOI: 10.1007/s11523-015-0394-5.

Preclinical Pharmacokinetics Evaluation of Anti-heparin-binding EGF-like Growth Factor (HB-EGF) Monoclonal Antibody Using Cynomolgus Monkeys via (89)Zr-immuno-PET Study and the Determination of Drug Concentrations in Serum and Cerebrospinal Fluid.

Kasai N, Adachi M, Yamano K Pharm Res. 2015; 33(2):476-86.

PMID: 26464296 DOI: 10.1007/s11095-015-1803-2.

References

Hikita S, Yotsumoto F, Fukami T, Fumaki T, Horiuchi S, Sanui A . Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA. Anticancer Res. 2011; 31(7):2553-9. View

Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H . A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. Clin Cancer Res. 2011; 17(21):6733-41. DOI: 10.1158/1078-0432.CCR-11-1029. View

Tanaka Y, Miyamoto S, Suzuki S, Oki E, Yagi H, Sonoda K . Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res. 2005; 11(13):4783-92. DOI: 10.1158/1078-0432.CCR-04-1426. View

Yamada A, Kawata S, Tamura S, Kiso S, Higashiyama S, Umeshita K . Plasma heparin-binding EGF-like growth factor levels in patients after partial hepatectomy as determined with an enzyme-linked immunosorbent assay. Biochem Biophys Res Commun. 1998; 246(3):783-7. DOI: 10.1006/bbrc.1998.8703. View

Kobrin M, Funatomi H, Friess H, Buchler M, Stathis P, Korc M . Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun. 1994; 202(3):1705-9. DOI: 10.1006/bbrc.1994.2131. View

Miyoshi E, Higashiyama S, Nakagawa T, Suzuki K, Horimoto M, Hayashi N . High expression of heparin-binding EGF-like growth factor in rat hepatocarcinogenesis. Int J Cancer. 1996; 68(2):215-8. DOI: 10.1002/(SICI)1097-0215(19961009)68:2<215::AID-IJC13>3.0.CO;2-9. View

Sanchez-Vizcaino E, Vehi C, Camprecios G, Morcillo C, Soley M, Ramirez I . Heparin-binding EGF-like growth factor in human serum. Association with high blood cholesterol and heart hypertrophy. Growth Factors. 2009; 28(2):98-103. DOI: 10.3109/08977190903443030. View

Sims P, Vasser M, Wong W, Williams P, Meng Y . Immunopolymerase chain reaction using real-time polymerase chain reaction for detection. Anal Biochem. 2000; 281(2):230-2. DOI: 10.1006/abio.2000.4578. View

Keay S, Kleinberg M, Zhang C, Hise M, WARREN J . Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production. J Urol. 2000; 164(6):2112-8. View

10.

Elenius K, Paul S, Allison G, Sun J, Klagsbrun M . Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 1997; 16(6):1268-78. PMC: 1169725. DOI: 10.1093/emboj/16.6.1268. View

11.

Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, Ishikawa M . Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell. 1995; 6(8):967-80. PMC: 301256. DOI: 10.1091/mbc.6.8.967. View

12.

Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T, Mekada E . Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci. 2006; 97(5):341-7. PMC: 11159358. DOI: 10.1111/j.1349-7006.2006.00188.x. View

13.

Higashiyama S, Abraham J, Miller J, Fiddes J, Klagsbrun M . A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991; 251(4996):936-9. DOI: 10.1126/science.1840698. View

14.

Higashiyama S, Nanba D . ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta. 2005; 1751(1):110-7. DOI: 10.1016/j.bbapap.2004.11.009. View

15.

Harris R, Chung E, Coffey R . EGF receptor ligands. Exp Cell Res. 2003; 284(1):2-13. DOI: 10.1016/s0014-4827(02)00105-2. View

16.

Higashiyama S, Lau K, Besner G, Abraham J, Klagsbrun M . Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem. 1992; 267(9):6205-12. View

17.

Keay S, Zhang C, Kagen D, Hise M, Jacobs S, Hebel J . Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. J Urol. 1997; 158(5):1983-8. DOI: 10.1016/s0022-5347(01)64198-3. View

18.

Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T . Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002; 8(1):35-40. DOI: 10.1038/nm0102-35. View

19.

Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S . Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer. 2008; 124(6):1429-39. DOI: 10.1002/ijc.24031. View

20.

Lind K, Kubista M . Development and evaluation of three real-time immuno-PCR assemblages for quantification of PSA. J Immunol Methods. 2005; 304(1-2):107-16. DOI: 10.1016/j.jim.2005.06.015. View